louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02986581: Prospective Cohort Study of Rapid Response Team
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hospital Medical Emergency Team
Medicine, Emergency
Hospital Rapid Response Team
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Seoul National University Bundang Hospital
First posted: 2016-12-08
Enrollment: 79800
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to general ward in Seoul National University Bundang Hospital and monitored by in-hospital rapid response system.

Brief summary: The purpose of this study is to collect data of rapid response team activated patients prospectively

Detailed description: acutely deteriorating patients including sudden cardiac arrest in general ward who are monitored and intervened by rapid response team

Eligibility criteria: Inclusion Criteria:

- Patients admitted to general ward in Seoul National University Bundang Hospital and monitored by in-hospital rapid response system.

Exclusion Criteria:

* patients admitted to pediatric wards
* patients in emergency room, intensive care unit, and operating room

Primary outcomes:
measure: mortality or ICU admission of rapid response team activated patient
timeFrame: an average of 1 year
measure: incidence of preventable cardiac arrest
timeFrame: an average of 1 year
Secondary outcomes:
measure: Frequency of triggerring criteria(1) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(2) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(3) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(4) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(5) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(6) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(7) for activation of rapid response team
timeFrame: an average of 1 year
measure: Frequency of triggerring criteria(8) for activation of rapid response team
timeFrame: an average of 1 year
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Yeon Joo Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02874781: Microcirculation of Patients With Kidney Transplant
Official title: Sublingual Microcirculation Data of Patients With Kidney Transplant
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Microcirculation
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2016-08-22
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with kidney transplant

Brief summary: This study measures the sublingual microcirculation of patients with kidney transplant using MicroScan. The data will be compared with data of health volunteers and end stage renal disease patients on hemodialysis.

Detailed description: This study measures the sublingual microcirculation of patients with kidney transplant using MicroScan. The data will be compared with data of health volunteers and end stage renal disease patients on hemodialysis. The microcirculation date includes total small vessel density, perfused small vessel density, proportion of perfused vessels, microvascular flow index, and heterogeneity index.

Eligibility criteria: Inclusion Criteria:

* patients with kidney transplant for more than one month

Exclusion Criteria:

* Body mass index (BMI) \< 18.5 or \> 30
* diagnosis of sepsis or trauma, or admitted to intensive care unit within one month before enrollment
* body temperature \< 35.5 or \> 37.5 Celsius
* patients with tongue resection
* non-native speaker

Primary outcomes:
measure: Total small vessel density
timeFrame: 6 hours
measure: Perfused small vessel density
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yu-Chang Yeh, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02517281: Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies
Official title: Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cancer
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2015-08-07
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.


Eligibility criteria: Inclusion Criteria:

* Patients with cancer beginning a targeted therapy
* Patients able to follow the protocol
* Age \>/= 18 years old
* Signed inform consent

Exclusion Criteria:

* Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
* Pregnant or breastfeeding woman

Primary outcomes:
measure: Number of clinical secondary effects bind to targeted therapies
timeFrame: Every 28 days up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Gustave Roussy Cancer Campus Grand Paris
state: Val De Marne
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Caroline Robert, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06984081: CAPA In-vitro Oocyte Maturation
Official title: CAPA In-vitro Oocyte Maturation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Infertility, Female
Keywords: In Vitro Oocyte Maturation Techniques
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2025-05-22
Enrollment: 100
Sex: FEMALE
Minimum age (years): 0
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.


Eligibility criteria: Inclusion Criteria:

* Patients aged from 0-50 years old
* Patients seek fertility preservation services
* Patients seek oocyte retrieval services

Exclusion Criteria:

-Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Primary outcomes:
measure: No. of mature oocytes
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chinese University of Hong Kong
name: Pui Wah Jacqueline Chung
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06220981: The Oslo Acute Reperfusion Stroke Study (OSCAR)
Official title: The Oslo Acute Reperfusion Stroke Study (OSCAR)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Ischemic Stroke
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2024-01-24
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: acute ischemic stroke patients with proximal cerebral artery occlusion admitted for endovascular treatment.

Brief summary: Prospective registry of clinical and radiological data in acute ischemic stroke patients after endovascular treatment.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Patients with ischemic stroke and cerebral arterial occlusion treated with endovascular revascularization.
* All stroke severities and vascular distributions are eligible.
* Informed written consent signed by the patient, verbal consent from the patient as witnessed by a non-participating health care person or consent by the signature of the patient's family must be provided before inclusion. Patients for whom no informed consent can be obtained will not be included in the study but will be treated according to standard guidelines.

Exclusion criteria:

• Patient not eligible for the study or not available for follow-up assessments (e.g. non- resident).

Primary outcomes:
measure: Modified Rankin Scale Score
timeFrame: 3 months
Secondary outcomes:
measure: National Institute of Health Stroke Scale Score
timeFrame: discharge
measure: Death due to any cause
timeFrame: 3 months
measure: Infarct volume
timeFrame: 1 day
measure: Incidence of symptomatic intracranial hemorrhage
timeFrame: 1 day
measure: Volume of new areas of diffusion restriction
timeFrame: 1 day
measure: serious adverse events
timeFrame: 3 months
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
References:
Clinical trial NCT06090981: Early Bolus Surfactant Replacement Therapy Versus Standard Care in Term Neonates With Meconium Aspiration Syndrome
Official title: Early Bolus Surfactant Replacement Therapy Versus Standard Care in Term (>=37 Weeks) Neonates With Actant Replacement Therapy Versus Standard Care in Term Neonates With Meconium Aspiration Syndrome: An Open Label Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Meconium Aspiration Syndrome
Surfactant Dysfunction
Lead sponsor: Lady Hardinge Medical College
Sponsor class: OTHER_GOV
First posted: 2023-10-19
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to compare the total duration of respiratory support in term neonates (≥37weeks) with meconium aspiration syndrome, who are provided early(≤2hr) bolus surfactant therapy versus standard care.

Detailed description: Enrolled participants will be randomly assigned to one of two study groups: 1. early(≤2hr) bolus surfactant replacement therapy or 2. standard care

Intervention group: The neonates enrolled in this group will receive early bolus surfactant replacement therapy within 2hr of life.

Control group: The neonates enrolled in this group will receive standard care according to standard unit protocol

Eligibility criteria: Inclusion Criteria:

* Gestation age ≥ 37 week
* Cephalic presentation
* Singleton pregnancy
* Age \< 2 hours
* Baby delivered through meconium stained amniotic fluid
* Presence of respiratory distress (DOWNE's score ≥4)

Exclusion Criteria:

* Major congenital malformation
* Antenatal diagnosed CHD
* Hydrops fetalis
* Air leaks before enrolment

Primary outcomes:
measure: Duration of Total respiratory support
timeFrame: Birth to 28 days
Secondary outcomes:
measure: Severity of respiratory distress
timeFrame: Birth to 28 days
measure: Proportion of neonates requiring mechanical ventilation
timeFrame: Birth to 28 days
measure: Proportion of neonates requiring Non Invasive Ventilation
timeFrame: Birth to 28 days
measure: Duration of Mechanical Ventilation
timeFrame: Birth to 28 days
measure: Duration of oxygen therapy
timeFrame: Birth to 28 days
measure: Complications
timeFrame: Birth to 28 days
measure: Mortality
timeFrame: Birth to 28 days
measure: Duration of hospital stay
timeFrame: Birth to 28 days
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Lady Hardinge Medical College
state: Delhi
Study officials:
affiliation: Lady Hardinge Medical College, New Delhi, India
name: Sushma Nangia, MD, DM (Neo)
role: STUDY_CHAIR
References:
Clinical trial NCT04805281: Wear Behavior of Milled Posterior Crowns Fabricated From the New Monolithic Zirconia 5Y-TZP/3Y-TZP Compared to Lithium Disilicate
Official title: Wear Behavior of Milled Posterior Crowns Fabricated From the New Gradient Technology Monolithic Zirconia 5Y-TZP/3Y-TZP Compared to Lithium Disilicate: (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Posterior Teeth
Worn Posterior Teeth
Endodontically Treated Teeth
Crowned Posterior Teeth
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-03-18
Enrollment: 24
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In-vitro studies do not represent the actual masticatory environment and cannot simulate the intricate chewing pattern. Hence, there is a need for an in vivo study evaluating the wear potential of the newly introduced strength - color gradient multilayered zirconia IPS e.max ZirCAD Prime (5Y-TZP/3Y-TZP) and compare it to Lithium Disilicate IPS e.max CAD which has proven to have favorable wear patterns.

Detailed description: * There will be no difference in wear caused by monolithic Zirconia (5Y-TZP/3Y-TZP) IPS E-max ZirCad Prime and Lithium Disilicate IPS e.max CAD to the antagonist.
* There will be no difference in the wear of the new monolithic zirconia IPS e.max ZirCAD Prime and lithium disilicate IPS e.max CAD.

Eligibility criteria: Inclusion Criteria:

* All subjects are required to:

  1- Be aged 21-50 years old, be able to read and sign the informed consent document. 2- Psychologically and physically able to withstand conventional dental procedures.

  3- Patients with mutilated posterior teeth indicated for full coverage restorations.

  4- Patients with sound natural antagonists. 5- Able to attend punctually for preplanned visits and evaluation. 6- Have no active periodontal or pulpal diseases.

  7- There should be no apparent loss or wear in opposing enamel.

Exclusion Criteria:

1. Patient with active resistant periodontal diseases.
2. Patients with parafunctional habits and bruxism.
3. Patients with poor oral hygiene, high caries risk and uncooperative patients. 3- Pregnant women.
4. Patients in the growth stage with partially erupted teeth. 5- Psychiatric problems or unrealistic expectations.

6- Lack of opposing dentition in the area of interest. 7- Restored occlusal surface opposing the planned restoration. 8- The presence of a removable or fixed orthodontic appliance.

Primary outcomes:
measure: The amount of occlusal wear in natural antagonist enamel caused by the restorative material
timeFrame: 1 year
Secondary outcomes:
measure: The amount of occlusal wear in the restorative material itself
timeFrame: 1 year
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT02691481: Diabetes-Specific Nutritional Formulas Versus Oatmeal
Official title: Effect of Diabetes-specific Formulas on Glucose Metabolism and GLP-1 Secretion in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Obesity
Lead sponsor: Joslin Diabetes Center
Sponsor class: OTHER
First posted: 2016-02-25
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: Diabetes-specific nutritional formulas (DSNFs) are frequently used as part of medical nutrition therapy for patients with type 2 diabetes in order to improve glycemic control and enhance weight reduction. The mechanism through which DSNFs improve postprandial (PP) plasma glucose is not yet known.

The aim of this study is to compare the effects of 2 DSNFs versus oatmeal on PP plasma glucose, serum insulin and serum active glucagon-like peptide-1 (GLP-1), serum free fatty acids (FFA) and serum triglycerides (TG).


Eligibility criteria: Inclusion Criteria:

* Patients with type 2 diabetes treated with oral diabetes medications

Exclusion Criteria:

* Type 1 diabetes

Primary outcomes:
measure: Glucose area under the curve 0-240 minutes
timeFrame: 240 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04123210: Estimating Average Vitamin A Requirements in Indonesian and American Women
Official title: Development of 13C-Retinol Isotope Dilution Techniques
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitamin A Deficiency
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: National Institute of Health Research and Development, Ministry of Health Republic of Indonesia
First posted: 2019-10-10
Enrollment: 70
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel assignment to 0 or 525 micrograms supplemental vitamin A/day (Indonesia) or 0, 175 or 525 micrograms supplemental vitamin A/day (USA).
Primary purpose: BASIC_SCIENCE

Brief summary: Women of reproductive age had their vitamin A stores estimated by retinol isotope dilution and then were given vitamin A supplements near the US vitamin A RDA or placebo for 42(USA) or 60 (Indonesia) days, after which retinol isotope dilution was repeated and the change in vitamin A stores was determined in each group to estimate how much vitamin A is needed to maintain nutrient balance in these women.


Eligibility criteria: Inclusion Criteria:

* Normal nutritional status (BMI 18.5-25)

Exclusion Criteria:

* Significant clinical illness

Primary outcomes:
measure: Total body vitamin A stores (micromoles of vitamin A)
timeFrame: Baseline and after 42 to 60 days
measure: Total vitamin A liver reserves (micromoles vitamin A per gram liver)
timeFrame: Baseline and after 42 to 60 days
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin - Madison
state: Wisconsin
city: Bogor
country: Indonesia
facility: Pusat Teknologi Terapan Kesehatan dan Epidemiologi Klinik
Study officials:
affiliation: University of Wisconsin, Madison
name: Sherry A Tanumihardjo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sheftel J, Valentine AR, Hull AK, Fadjarwati T, Gannon BM, Davis CR, Tanumihardjo SA. Findings in 3 clinical trials challenge the accuracy of the Institute of Medicine's estimated average requirements for vitamin A in children and women. Am J Clin Nutr. 2021 May 8;113(5):1322-1331. doi: 10.1093/ajcn/nqaa132.
Clinical trial NCT06669910: Investıgatıon of Temporomandıbular Dysfunctıon in Patıents Wıth Breast Cancer-Related Lymphedema
Official title: Investıgatıon of Temporomandıbular Dysfunctıon in Patıents Wıth Breast Cancer-Related Lymphedema
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Lymphedema
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
Collaborators: name: Gazi University
First posted: 2024-11-01
Enrollment: 38
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Female patients who were treated for unilateral breast cancer and developed breast cancer-related LE

Brief summary: This study is the first study to examine temporomandibular joint dysfunction (TMD) in patients with breast cancer. The aim of the study was to investigate the relationship between lymphedema (LÖ) and TMD in patients with breast cancer. Socio-demographic characteristics of 38 individuals included in the study were recorded. Patients were divided into stage 0, 1 and 2 groups according to their LÖ stage and mild, moderate and advanced groups according to their TMD levels. In the evaluation of severity of lymphedema, Symptoms and Signs of TMD, pain threshold and tolerance assessment and normal range of motion, anxiety and depression, posture analysis environmental measurement, Craniomandibular Dysfunction Index for Clinical, Visual Analogue Scale (VAS) and algometer , goniometer and inclinometer, Turkish version of the Hospital Anxiety and Depression Scale (HAD) ,photogrammetric assessment method and inclinometer were used


Eligibility criteria: Inclusion Criteria:

* Female patients aged 18-75 years who were treated for unilateral breast cancer and developed breast cancer-related LE were included in the study

Exclusion Criteria:

* Patients with general joint diseases affecting the head and neck region that may cause TMD (e.g. rheumatoid arthritis),
* jaw fracture,
* trauma or orthognathic surgery history,
* cervical disc herniation,
* congenital disease,
* facial paralysis,
* patients who have been treated for TMD for the last 3 months and patients who use antidepressant drugs were excluded.

Primary outcomes:
measure: temporomandibular dysfunction
timeFrame: through study completion, an average of 1 year
measure: lymhedema
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: pain
timeFrame: through study completion, an average of 1 year
measure: posture
timeFrame: through study completion, an average of 1 year
measure: Measurement of range of motion of cervical joints and shoulder joint
timeFrame: through study completion, an average of 1 year
measure: anxiety-depression
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Arife Akbulut
Study officials:
References: